VCNX (Vaccinex) Cash-to-Debt : 49.25 (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Vaccinex Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vaccinex's cash to debt ratio for the quarter that ended in Sep. 2024 was 49.25.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Vaccinex could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Vaccinex's Cash-to-Debt or its related term are showing as below:

VCNX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.41 Med: 12.12 Max: No Debt
Current: 49.25

During the past 8 years, Vaccinex's highest Cash to Debt Ratio was No Debt. The lowest was 0.41. And the median was 12.12.

VCNX's Cash-to-Debt is ranked better than
71.34% of 1483 companies
in the Biotechnology industry
Industry Median: 7.46 vs VCNX: 49.25

Vaccinex Cash-to-Debt Historical Data

The historical data trend for Vaccinex's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Vaccinex Cash-to-Debt Chart

Vaccinex Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

1.15

22.02

13.18

6.22

Vaccinex Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															0.41	6.22	16.07	1.91	49.25

Competitive Comparison of Vaccinex's Cash-to-Debt

For the Biotechnology subindustry, Vaccinex's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaccinex's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaccinex's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Vaccinex's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Vaccinex Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Vaccinex's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.535	/	(0.221	+	0.026)
	=	6.21

Vaccinex's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.906	/	(0.059	+	0)
	=	49.25

Vaccinex (OTCPK:VCNX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Vaccinex Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Vaccinex's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaccinex Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaccinex Inc (OTCPK:VCNX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1895 Mount Hope Avenue, Rochester, NY, USA, 14620

Website

https://www.vaccinex.com

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Executives

Albert Friedberg	director, 10 percent owner
Van Strydonck, Gerald E.	director	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Maurice Zauderer	director, 10 percent owner, officer: President and CEO	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Jacob B. Frieberg	director	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Elizabeth E. Evans	officer: Chief Operating Officer	C/O VACCINEX, INC., 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Robert Scala	officer: Chief Commercial Officer	1895 MT HOPE AVENUE, ROCHESTER NY 14620
Chrystyna Bedrij Stecyk	director	1895 MT. HOPE AVENUE, ROCHESTER NY 14620
Vaccinex, Inc.	director	1895 MOUNT HOPE AVE, ROCHESTER NY 14620
Jeff Goater	director	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Bala S Manian	director	1025 TERRA BELLA AVE, MOUNTAIN VIEW CA 94043
Barbara Yanni	director	1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Alejandro M. Berlin	director	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
John E. Leonard	officer: SVP, Development	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Ernest S. Smith	officer: SVP, Research & CSO	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Raymond E. Watkins	officer: SVP & Chief Operating Officer	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620